Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension

被引：31

作者：

Barst, Robyn J.

机构：

[1] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[2] New York Presbyterian Pulm Hypertens Ctr, New York, NY USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 01期

关键词：

endothelin-1; endothelin receptor antagonist; pulmonary arterial hypertension;

D O I：

10.1517/14656566.8.1.95

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective enclothelin-A receptor antagonist, is an effective, safe and well-tolerated enclothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials have demonstrated that sitaxsentan has beneficial effects on exercise capacity (i.e., 6-min walk distance), functional class and hemodynamic parameters in PAH patients. Sitaxsentan has a low incidence of acute hepatotoxicity. Patients on concomitant warfarin require a decrease in warfarin dose to maintain a therapeutic international normalized ratio. The demonstration of clinical efficacy and low incidence of acute hepatotoxicity support the potential use of sitaxsentan for the treatment of PAH.

引用

页码：95 / 109

页数：15

共 49 条

[1]

Abraham DJ, 1997, AM J PATHOL, V151, P831

[2] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[3] Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].

Barst, RJ ;

Ivy, D ;

Dingemanse, J ;

Widlitz, A ;

Schmitt, K ;

Doran, A ;

Bingaman, D ;

Nguyen, N ;

Gaitonde, M ;

van Giersbergen, PLM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382

[4] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[5] Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].

Barst, RJ ;

Rich, S ;

Widlitz, A ;

Horn, EM ;

McLaughlin, V ;

McFarlin, J .

CHEST, 2002, 121 (06) :1860-1868

[6] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[7] Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[8] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].

Barst, Robyn J. ;

Langleben, David ;

Badesch, David ;

Frost, Adaani ;

Lawrence, E. Clinton ;

Shapiro, Shelley ;

Naeije, Robert ;

Galie, Nazzareno .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056

[9] Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension [J].

Bauer, M ;

Wilkens, HC ;

Langer, F ;

Schneider, SO ;

Lausberg, H ;

Schäfers, HJ .

CIRCULATION, 2002, 105 (09) :1034-1036

[10]

BENZA RL, 2006, 26 ISHLT ANN M SCI S, P94

← 1 2 3 4 5 →